company background image
ALIC

I.CERAM ENXTPA:ALICR Stock Report

Last Price

€14.35

Market Cap

€4.2m

7D

0.4%

1Y

-48.0%

Updated

22 May, 2022

Data

Company Financials +
ALICR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

ALICR Stock Overview

I.CERAM SA designs, manufactures, and markets alumina-based ceramic implants in France and internationally.

I.CERAM Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for I.CERAM
Historical stock prices
Current Share Price€14.35
52 Week High€35.20
52 Week Low€9.90
Beta1.29
1 Month Change-7.42%
3 Month Change7.49%
1 Year Change-48.01%
3 Year Change-77.08%
5 Year Change-89.19%
Change since IPO-88.96%

Recent News & Updates

May 04
Would I.CERAM (EPA:ALICR) Be Better Off With Less Debt?

Would I.CERAM (EPA:ALICR) Be Better Off With Less Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Shareholder Returns

ALICRFR Medical EquipmentFR Market
7D0.4%2.8%-1.3%
1Y-48.0%-5.9%-5.4%

Return vs Industry: ALICR underperformed the French Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: ALICR underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALICR's price volatile compared to industry and market?
ALICR volatility
ALICR Average Weekly Movement14.8%
Medical Equipment Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in FR Market10.5%
10% least volatile stocks in FR Market3.6%

Stable Share Price: ALICR is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ALICR's weekly volatility has increased from 9% to 15% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200533André Kérisithttps://www.iceram.fr

I.CERAM SA designs, manufactures, and markets alumina-based ceramic implants in France and internationally. It offers implants for various joints of the human body, including skull, shoulder, spine, hip, tibia, ankle, foot, and thorax, as well as osteosynthesis products. The company was founded in 2005 and is headquartered in Limoges, France.

I.CERAM Fundamentals Summary

How do I.CERAM's earnings and revenue compare to its market cap?
ALICR fundamental statistics
Market Cap€4.19m
Earnings (TTM)-€1.44m
Revenue (TTM)€1.66m

2.5x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALICR income statement (TTM)
Revenue€1.66m
Cost of Revenue€401.86k
Gross Profit€1.26m
Other Expenses€2.70m
Earnings-€1.44m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-4.92
Gross Margin75.85%
Net Profit Margin-86.44%
Debt/Equity Ratio131.7%

How did ALICR perform over the long term?

See historical performance and comparison

Valuation

Is I.CERAM undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.3x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALICR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALICR's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALICR is unprofitable, so we can't compare its PE Ratio to the French Medical Equipment industry average.

PE vs Market: ALICR is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALICR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALICR is overvalued based on its PB Ratio (2.3x) compared to the FR Medical Equipment industry average (2.2x).


Future Growth

How is I.CERAM forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


67.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALICR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: ALICR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALICR's is expected to become profitable in the next 3 years.

Revenue vs Market: ALICR's revenue (31.5% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALICR's revenue (31.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALICR's Return on Equity is forecast to be low in 3 years time (8.3%).


Past Performance

How has I.CERAM performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALICR is currently unprofitable.

Growing Profit Margin: ALICR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALICR is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.

Accelerating Growth: Unable to compare ALICR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALICR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).


Return on Equity

High ROE: ALICR has a negative Return on Equity (-78.81%), as it is currently unprofitable.


Financial Health

How is I.CERAM's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALICR's short term assets (€3.9M) exceed its short term liabilities (€2.2M).

Long Term Liabilities: ALICR's short term assets (€3.9M) exceed its long term liabilities (€2.1M).


Debt to Equity History and Analysis

Debt Level: ALICR's net debt to equity ratio (78.1%) is considered high.

Reducing Debt: ALICR's debt to equity ratio has increased from 15% to 131.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALICR has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALICR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is I.CERAM current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALICR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALICR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALICR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALICR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALICR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average board tenure


CEO

André Kérisit (55 yo)

no data

Tenure

€115,800

Compensation

Mr. André Kérisit serves as the Chief Executive Officer and President of I.CERAM SAS and has been its Chairman and Director since May 15, 2013.


CEO Compensation Analysis

Compensation vs Market: André's total compensation ($USD122.16K) is below average for companies of similar size in the French market ($USD284.13K).

Compensation vs Earnings: André's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: ALICR's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

I.CERAM SA's employee growth, exchange listings and data sources


Key Information

  • Name: I.CERAM SA
  • Ticker: ALICR
  • Exchange: ENXTPA
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €4.192m
  • Shares outstanding: 292.11k
  • Website: https://www.iceram.fr

Number of Employees


Location

  • I.CERAM SA
  • 1 rue Columbia
  • Parc d’Ester Technopole
  • Limoges
  • Limousin
  • 87068
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.